

Index

- abattoir workers, 69–73
 abscess, cerebral, 121–152, 188–200
N-acetyltransferase, 156–166
 aciclovir, 98–124, 155–163
 acute necrotising ulcerative gingivitis, 26–40
 acyclovir, 110–135
 ADC (AIDS dementia complex), 187–199
 adenosine deaminase deficiency, 8–21
 adenovirus, 69–73, 193–205
 Advisory Committee on Dangerous Pathogens, 60–62, 61–63
 AIDS, 187–202
 air sampling, 84–95
 albendazole, 220–235
 Albert's stain, 5–17
 alcohol hand gel, 79–85
 amantadine, 154–163
 aminoglycosides. *See also specific agents*
 adverse events of, 160–173
 mechanisms of action of, 155–173
 post-dose effect of, 155–164
 resistance to, 117–147, 155–164
 amoebiasis, 8–20
 amoebic meningoencephalitis, 102–128
 amoxicillin, 112–147, 156–165
 amphotericin B, 102–128, 177, 190–205
 ampicillin, 7–18
 anaemia, 36–58
 anaplasmosis, 211–222
Ancylostoma braziliense, 119, 119–150
Ancylostoma duodenale, 36–58
 animal reservoirs, 210–221
 anisakiasis, 214–227
 anthrax, 105–130
 antibiotic resistance
 Campylobacter species, 157–168
 enterococci, 80–86, 117–147
 mechanisms of action of, 154–173
 metabolism of, 156–166
 for neonatal sepsis, 111–137
 peri-operative prophylaxis, 112–139
 resistance to (*See* antibiotic resistance)
 safety categories, 156–165
 antiretroviral therapy. *See also specific antiretrovirals*
 initiation of, 187–202
 post exposure prophylaxis, 191–204
 in pregnancy, 191–203
 resistance to, 191–203
 switches in, 191–203
 virological response to, 190–202
 antiviral therapy, 154–163, 272.60. *See also specific antivirals*
 aplastic crisis, 2–11
 artemisinin, 218–235
 artesunate, 219–235
 arthritis, reactive, 122–153
Aspergillus flavus, 196–207
Aspergillus species, 162–177
 astrovirus, 70–76
 asymptomatic bacteriuria, 30–47, 30–47, 114–142, 115–143, 115–143
 atovaquone-proguanil, 218–235
 autoclave, 83–91
 avian chlamydiosis, 28–43
 avian influenza virus, 213–225
 azithromycin, 7–19, 109–149, 157–168

 B cells, 9–23
 babesiosis, 211–222
Bacillus anthracis, 105–130
Bacillus cereus, 69–76
 bacteraemia, 34–56
 antimicrobial prophylaxis for, 112–139
 Listeria monocytogenes, 33–54
 Staphylococcus aureus, 114–141, 114–141, 159–171, 159–172

Escherichia coli, 3–13, 117–148
 genetic transfer of, 3–13
Klebsiella pneumoniae, 7–19, 79–85, 122–152
mcr-1 gene, 79–85
 mechanisms of, 155–164
 MRSA, 80–86
Mycobacterium species, 82–90
Pseudomonas aeruginosa, 161–175
Salmonella species, 215–229
 screening for, 29–45
Staphylococcus haemolyticus, 29–45
Stenotrophomonas maltophilia, 118–148
Streptococcus pneumoniae, 156–166
 antifungal therapy, 161–176.
 See also specific antifungals
 prophylaxis, 162–177
 antigenic drift, 179–182
 antigenic variation, 5–17
 antigens
 bacterial, 3–17
 hepatitis virus, 25–39
 antimicrobial therapy, 154. *See also specific antimicrobials*
 adverse events of, 157–176
 allergy to, 159–171
 alternatives to, 162–178
 blood brain barrier and, 156–165
 for bloody diarrhoea, 70–76
Clostridium difficile infection and, 81–89
 community contact prophylaxis, 69–75
 drug interactions of, 158–175
 febrile neutropenia management guidelines, 195–207
 in haemolytic uraemic syndrome, 71–77
 healthcare worker prophylaxis, 69–74
 malaria prophylaxis, 218–233

- Staphylococcus haemolyticus*, 29–45
- Streptococcus gallolyticus*, 33–54
- bacteria, 1. *See also specific bacteria*
- antibiotic resistance in (See antibiotic resistance)
- antigens of, 3–17
- capsules of, 6, 18
- cell membrane of, 155–174
- cell walls of, 3–15
- genetic transfer among, 3–13
- Gram stain of (See Gram stain)
- identification of, 3–18
- selective media for, 29–54
- toxins of, 4–22, 32–51, 105–130
- urease producing, 5–15
- virulence factors of, 5–16, 18
- bacteriophages, 5–17, 162–178
- Baltimore classification system, 1–10
- Bartonella henselae*, 104–133
- bats, rabies transmission by, 24–37
- benzathine penicillin, 109–135
- benzylpenicillin, 109–137, 159–171
- beta-lactamase, 3–19, 29–45, 117–148, 161–175, 215–229
- beta-lactams. *See also specific agents*
- allergy to, 159–171
- drug interactions of, 160–174
- for enterococcal endocarditis, 117–147
- for *Escherichia coli*, 117–148, 160–174
- for *Pseudomonas aeruginosa*, 198–209
- for *Staphylococcus aureus*, 159–171
- biosafety cabinets, 60–62
- black legged tick, 211–222
- blood brain barrier, 156–165
- blood films, 36–59
- blood samples, laboratory health and safety for, 61–65, 61–66, 66
- bloody diarrhoea
- Shigella* species, 70–75, 116–145
- transmission of, 71–78
- treatment of, 70–76
- bone marrow samples, 32–50
- Bordetella pertussis*, 7–19, 68–72, 112–138
- Bornholm's disease, 106–132
- Borrelia burgdorferi*, 99–126, 211–222
- Borrelia recurrentis*, 5–17
- brain abscess, 121–152, 188–200
- bronchoalveolar lavage, 35–58
- brucellosis, 61–64, 213–226
- Burkholderia pseudomallei*, 218–231
- C7 deficiency, 8–21
- calcofluor staining, 35–57
- Campylobacter fetus*, 33–53
- Campylobacter jejuni*, 157–168, 197–209
- Campylobacter* species, 69–73, 197–208
- cancer. *See malignancy*
- Candida albicans*, 34–56
- CAP (community acquired pneumonia), 113–140, 213–225
- Capnocytophaga canimorsus*, 107–133
- capsule, bacterial, 6, 18
- carbapenemase, 7–19, 79–85, 122–152
- carbapenems. *See also specific agents*
- drug interactions of, 160–174
- for *Escherichia coli*, 117–148
- carbol fuchsin, 3–12
- Cary-Blair (CB) media, 32–51
- case-control study, 82–89
- case-finding study, 82–89
- caspofungin, 177
- Castleman's disease, 188–200
- cat scratch disease, 104–133
- catalase, *Shigella* species, 33–53
- catheter-associated UTI, 114–142, 115–142
- CD4 count, 188–199
- cefotaxime, 29–45, 159–171
- cefoxitin, 29–45
- cefpodoxime, 29–45
- ceftaroline, 161–175
- ceftazidime, 29–45, 218–231
- ceftobiprole, 161–175
- ceftolozane-tazobactam, 161, 161–175
- ceftriaxone, 117–149, 215–229
- cell membrane, bacterial, 155–164, 160–174, 160–173
- cell walls, bacterial, 3–15
- cephalosporins. *See specific agents*
- cerebral abscess, 121–152, 188–200
- cerebrospinal fluid (CSF)
- HSV diagnosis using, 25–39
- India Ink stain on, 103–129
- measles virus, 97–123
- CGD (chronic granulomatous disease), 8–22, 197–208
- chancere, 110–136
- chancroid, 215–230
- Chlamydia psittaci*, 28–43
- Chlamydia trachomatis*, 26–43, 109–136
- chlonorchiasis, 214–227
- chloramphenicol, 29–43, 158–170, 212–223
- chloroquine, 218–235
- chocolate bacitracin agar, 30–46, 30–46, 46
- cholera, 33–52, 180–184, 214–229
- chronic carriage, 217–230
- chronic granulomatous disease (CGD), 8–22, 197–208
- chronic obstructive pulmonary disease (COPD), 34–55
- chronic viral infection, 2–12
- ciprofloxacin, 70–75, 157–166
- cirrhosis, vaccination and, 180–183
- CL2 (Containment Level 2), 61–65
- CL3 (Containment Level 3), 60–63
- clarithromycin, 7–19, 213–225
- clindamycin, 81–87, 156–166, 188–200
- clinical syndromes, 96. *See also specific syndromes*
- Clostridium difficile*, 80–89, 99–125
- Clostridium sordellii*, 107–150
- Clostridium tetani*, 24–37
- coagulase test, *Staphylococcus* species, 29–45
- co-amoxiclav, 107–148, 213–225
- coccidiomycosis, 34–56
- cognitive decline, UTIs and, 115–143

- cohort study, 82–89
 colistin, 29–43, 79–85, 122–152
 colon cancer, 33–54
 community acquired pneumonia (CAP), 113–140, 213–225
 community contacts,
 meningococcal
 prophylaxis for, 69–75
 congenital CMV infection,
 98–125, 106–132
 congenital rubella syndrome,
 26–40
 congenital syphilis, 109–137
 conjugate vaccines, 179–182
 conjugation, 3–13
 conjunctivitis
 adenovirus, 193–205
 Chlamydia trachomatis,
 109–134
 dirofilariasis, 101–127
 contact tracing, 83–91
 Containment Level 2 (CL2),
 61–65
 Containment Level 3 (CL3),
 60–63
 COPD (chronic obstructive
 pulmonary disease), 34–55
 coronavirus, MERS, 220–235
Corynebacterium diphtheriae,
 5–17, 118–148
Corynebacterium
 pseudodiphtheriticum,
 103–129
Corynebacterium ulcerans, 6–17
 co-trimoxazole, 118–148,
 162–177, 192–204, 218–231
 cough, pertussis, 7–19, 68–72,
 112–138
Coxiella burnetii, 68–72
 coxsackie virus, 79–85, 106–132
 creatine phosphokinase, 160–174
 cross-sectional study, 82–89
 croup, 1–10, 106–131
Cryptococcus neoformans,
 103–129, 103–129, 128,
 192–205
Cryptosporidium parvum,
 68–72, 215–228
 crystal violet, 3–12
 CSF. *See* cerebrospinal fluid
 culture
 blood, 34–56
 broth, 34–55
 Campylobacter species, 33–53
 Mycobacterium marinum,
 112–138
 selective media for, 29–54
 stool, 31–51, 214–228
 cutaneous larva migrans,
 119, 119–150
Cyclospora cayetanensis, 32–50
 cystic fibrosis (CF), 30–46,
 99–148
 cytokines, 9–23
 cytomegalovirus (CMV), 98–132,
 210–221
 dapsone, 157–169
 daptomycin, 117–147, 160–174
 decontamination, laboratory,
 62–67
 dental antimicrobial
 prophylaxis, 112–139
 diarrhoea
 Campylobacter jejuni, 197–209
 Clostridium difficile, 81–88
 Cryptosporidium parvum,
 215–228
 diagnostic tests for, 25–38
 Entamoeba histolytica, 8–20
 giardiasis, 70–76
 healthcare associated, 80–89
 Listeria monocytogenes,
 116–146
 outbreaks of, 69–78, 82–94,
 116–145
 public health notification in
 cases of, 70–75
 return to work after, 83–92
 Salmonella species, 3–14,
 34–54, 116–144
 Shigella species, 34–54, 70–75,
 116–145
 transmission of, 71–78
 travellers', 116–145, 214–227
 treatment of, 70–76
 Vibrio species, 115–144,
 214–229
 Yersinia enterocolitica,
 116–145
 diphtheria, 5–17, 118–148
 diphtheria toxin, 5–17
Diphyllobothrium latum,
 210–221, 214–227
 dirofilariasis, 101–127
 disinfectants, 66
 disinfection, 81–91
 DNA viruses, 1–10
 DNase, 5–16, 34–55
 dog bites, 24–37, 107–133
 double stranded DNA viruses,
 1–10
 double stranded RNA viruses,
 1–10
 doxycycline, 211–233
 drug monitoring, 156–176
 echinocandins, 192–205
 eEF2 (eukaryotic elongation
 factor-2), 5–17
 efavirenz, 191–203
 electron microscopy, 1–9, 25–38
 encephalitis
 Bartonella henselae, 104–130
 diagnostic tests for, 25–39
 measles virus, 97–123
 primary amoebic, 102–128
 toxoplasma, 188–200
 endocarditis, 7–18
 diagnostic tests for, 34–56
 enterococcal, 117–147
 peri-operative antimicrobial
 prophylaxis for, 112–139
 prosthetic valve, 103–129,
 159–172
 endotoxins, 4–16
Entamoeba dispar, 8–20
Entamoeba histolytica, 8–20
Entamoeba moshkovskii, 8–20
 enteric fever
 chronic carriage of, 217–230
 diagnostic tests for, 32–50
 return to work after, 83–92
 Salmonella species, 215–230
 enteritis. *See also* diarrhoea
 Campylobacter species, 33–53,
 157–168
 Cyclospora cayetanensis,
 32–50
 food-borne, 32–51
 outbreaks of, 69–73
 Salmonella species, 31–54
 Shigella dysenteriae, 33–53
 transport media for, 32–51
 Vibrio cholerae, 33–52
Enterobius vermicularis, 36–59
Enterococcus faecalis, 117–147
Enterococcus faecium, 7–18
Enterococcus species,
 antibiotic resistance in,
 80–86, 117–147
 enterotoxins, 5–16, 32–51
 envelope, viral, 1–9, 79–85
 epidemic typhus, 7–20
 Epstein Barr Virus (EBV),
 97–124
 erythema chronicum migrans,
 99–126

- erythema infectiosum, 2–11
erythema migrans, 211–222
erythema nodosum, 100–126
erythromycin, 7–19, 109–146,
156–168, 197–209
Erythroviruses, 2–11
ESBL (extended spectrum beta-
lactamase), 3–19, 29–45,
117–148, 161–175,
215–229
Escherichia coli
antibiotic resistance of, 3–13,
117–148
diarrhoea, 116–145, 214–227
empiric therapy for, 159–171
neonate infection with, 4–14
O157:H7 treatment, 71–77
UTI, 5–15, 114–140
ethambutol, 156–165
eukaryotic elongation factor-2
(eEF2), 5–17
exanthem subitum, 193–205
exotoxins, 5–17
- facultative anaerobes, 4–15
faecal specimens
cholera, 215–229
culture of, 31–51, 214–228
transport media for, 32–51
famciclovir, 110–135
fast acetylators, 156–166
febrile neutropenia, 195–207
Field's stain, 36–59
fish tank granuloma, 112–138
flucloxacillin, 159–172
fluconazole, 162–177, 192–205
flucytosine, 161–176, 192–205
fluoroquinolones. *See also*
specific agents
mechanism of action of,
157–166
resistance to, 82–89
for *Salmonella Typhi*, 217–230
for tuberculous meningitis,
156–165
- food-borne infection
anisakiasis, 214–227
avian influenza virus, 213–225
diagnostic tests for, 32–51
food preparation policy and,
83–93
giardiasis, 70–76
in immunocompromised
patients, 197–208
Listeria monocytogenes,
83–93, 116–146, 116–146
- outbreaks, 69–78
public health notification of,
70–75
Salmonella species, 71–77,
83–92
transmission of, 71–78
treatment of, 70–76
vaccination for, 180–184
Vibrio species, 33–52,
107–144, 214–229
Yersinia enterocolitica,
116–145
formaldehyde, 62–67
Francisella tularensis, 212–223
fumigation, laboratory, 61–67
fungi, 1. *See also specific fungi*
diagnostic tests for, 34–58
Fusarium solani, 195–206
fusidic acid, 155–164
Fusobacterium necrophorum,
111–137
- ganciclovir, 189–201
gastric acid suppressants, 80–87,
99–125
genetic transfer, bacteria, 3–13
genital cancer, HPV association
with, 2–11
genital herpes, 110–135
genital ulcers, 110–136, 215–230
genotyping, 31–48
gentamicin, 111–147, 155–173
Giardia lamblia, 68–72,
122–153
giardiasis, 70–76, 116–145
Giemsa stain, 36–59
glycopeptide resistant
enterococci (GRE), 80–86,
117–147
GMS (Grocott methenamine
silver), 35–57
gnathostomiasis, 214–227
gonorrhoea, 27–41, 118–149
Gram stain, 3–12
Neisseria gonorrhoea, 27–41
Vincent's angina, 26–40
gray baby syndrome, 158–170
Gridley's fungus (GF), 35–57
griseofulvin, 162–176
Grocott methenamine silver
(GMS), 35–57
group A *Streptococcus*, 29–44,
100–126
group B *Streptococcus*, 4–14,
159–171
group C *Streptococcus*, 29–44
- H antigens, 3–14
haematuria
diagnostic tests for, 31–49
schistosomiasis, 214–234
haemolytic uraemic syndrome,
70–77
Haemophilus ducreyi, 215–230
Haemophilus influenzae, 30–55
hand hygiene, 79–94
hazard groups, 60–63
HBsAg (hepatitis B surface
antigen), 25–39
HBV. *See* hepatitis B virus
HCV (hepatitis C virus), 2–22
health and safety, 60
biosafety cabinets, 60–62
blood samples, 61–66
CL2, 61–65
CL3, 60–63
hazard groups, 60–63
laboratory decontamination,
62–67
specimen transport, 61–65
workplace-associated
infection among
laboratory workers, 61–64
healthcare associated infection
catheter-associated UTIs,
114–142
diarrhoea, 80–89
healthcare workers
meningococcal prophylaxis
for, 69–74
return to work advice for,
83–92
hearing loss
aminoglycosides causing,
160–173
CMV infection, 98–132
hepatitis, antimicrobial therapy
causing, 157–167
hepatitis B surface antigen
(HBsAg), 25–39
hepatitis B virus (HBV)
diagnostic tests for, 25–39
laboratory health and safety
for, 61–66
laboratory worker infection
with, 61–64
vaccination for, 179–181
hepatitis C virus (HCV), 2–22
hepatitis E virus (HEV),
106–131
heroin use, 105–130
herpes simplex virus (HSV),
25–39, 110–135

- HEV (hepatitis E virus), 106–131
- HHV6 (human herpes virus 6), 193–205
- hidradenitis suppurativa (HS), 103–129
- histoplasmosis, 101–127
- HIV. *See* human immunodeficiency virus
- HIV-associated nephropathy (HIVAN), 187–199
- Hodgkin's lymphoma, 97–124
- hookworms, 36–58, 119–150, 210–228
- host-pathogen interactions, 1
- HPV (human papillomavirus), 2–11
- HRIG (human rabies immunoglobulin), 24–37
- HTLV-1 (human T-lymphotropic virus 1), 97–123
- human herpes virus 6 (HHV6), 193–205
- human immunodeficiency virus (HIV), 187
 antiretroviral therapy for (*See* antiretroviral therapy)
Campylobacter infection in, 33–53
Cryptococcus neoformans infection in, 192–205
 end-organ diseases caused by, 187–199
 Kaposi's sarcoma in, 189–201
 multicentric Castleman's disease in, 188–200
 PCP in, 192–208
 penicilliosis in, 190–201
 post exposure prophylaxis for, 191–204
 pregnancy and, 191–203
 prognostic laboratory tests for, 188–199
 seroconversion illness in, 187–198
 syphilis co-infection with, 217–230
Toxoplasma gondii infection in, 188–200
 virological response in, 190–202
- human normal immunoglobulin, 154–163
- human papillomavirus (HPV), 2–11
- human rabies immunoglobulin (HRIG), 24–37
- human T-lymphotropic virus 1 (HTLV-1), 97–123
- hyalohyphomycosis, *Paecilomyces lilacinus*, 194–206
- hyperammonaemia, 5–15
- hypogammaglobulinaemia, 197–209
- IFNs (interferons), 9–23
- IgM, 8–21
- IgM deficiency, 8–21
- imipenem, 160–174
- immune response
 defects in, 8–22, 197–209
 immunoglobulins in, 8–21
 Th1 and Th2, 9–23
 TLRs in, 9–22
- immunocompromised patients, 187. *See also* human immunodeficiency virus
- adenovirus infection in, 193–205
- antifungal prophylaxis in, 162–177
- Aspergillus flavus* infection in, 196–207
- Campylobacter jejuni* infection in, 197–209
- febrile neutropenia in, 195–207
- food-borne infection in, 197–208
- Fusarium solani* infection in, 195–206
- HEV infection in, 106–131
- HHV6 infection in, 193–205
- meningitis in, 103–129
- Paecilomyces lilacinus* infection in, 194–206
- Pseudomonas aeruginosa* infection in, 196, 198–209
- vaccination in, 179–183
- immunodeficiency, 8–22, 197–209
- immunoglobulin (Ig), 8–21
 defects in, 8–21, 197–209
 diagnostic tests using, 26–40
 HRIG, 24–37
 human normal, 154–163
- incomplete virological response, 190–202
- India, cholera in, 215–229
- India Ink stain, 103–129
- infection control guidelines, 68–72
- infection prevention and control, 79
- air sampling, 84–95
- anaesthetic airway devices, 83–91
- case-control studies, 82–89
- for *Clostridium difficile* infection, 81–89
- food preparation, 83–93
- for GRE, 80–86
- hand hygiene, 79–94
- for healthcare associated diarrhoea, 80–89
- for KPC, 79–85
- for MRSA, 80–86
- prevalence studies, 82–89
- return to work advice, 83–92
- sterilization, 81–91
- tuberculosis, 82–91
- UCV theatres, 84–94
- ward closure for diarrhoea outbreaks, 82–93
- influenza virus, 2–11
 antiviral therapy for, 154–163
- avian strains, 213–225
- vaccination for, 179–182
- innate defence peptides, 162–178
- interferons (IFNs), 9–23
- interleukins (ILs), 9–23
- intravenous drug use
 anthrax infection in, 105–130
- Clostridium sordellii* infection in, 107–150
- vaccination for, 179–181
- iodide, 3–12
- iron deficiency anaemia, 36–58
- isolation
 of influenza virus patients, 213–225
 of tuberculosis patients, 82–90
- isoniazid, 156–166
- itching, scabies, 108–134
- itraconazole, 177
- ivermectin, 7–20, 68–72, 108–150, 220–235
- Ixodes scapularis*, 211–222
- Job syndrome, 8–21
- joint replacement surgery, 84–94, 113–139, 113–139
- Kaposi's sarcoma (KS), 189–201
- kerato-conjunctivitis, 193–205
- ketconazole, 218–231

- Kikuchi's disease, 100–127
killed vaccines, 179–182
Klebsiella pneumoniae, 7–19,
79–85, 122–152
Klebsiella pneumoniae
carbapenemase (KPC),
7–19, 79–85, 122–152,
122–152
- laboratory decontamination,
62–67
laboratory safety. *See* health
and safety
lactophenol cotton blue stain,
35–58
lactose fermentation, 31–49
laminar air flow, 84–94
lamivudine, 155–163
lansoprazole, 99–125
laryngotracheobronchitis, 1–10,
106–131
latent viral infection, 2–12
latex agglutination tests, 29–44
lecthinase, 5–16
Legionella species, 113–140,
213–225
Lemierre's syndrome, 111–137
leprosy, 157–169
leukocyte esterase test, 30–47
light microscopy, *Enterobius
vermicularis*, 36–59
lincosamides, 156–166. *See also
specific agents*
linezolid, 117–147, 158–170
lipid A, 5–16
lipopolysaccharide (LPS), 5–22
lipoteichoic acid (LTA), 4–15
Listeria monocytogenes, 4–14,
33–54, 83–93, 116–146
live vaccines, 179–183
louse-borne relapsing fever,
5–17
louse-borne typhus, 7–20
Lowenstein-Jensen media,
112–138
Lyme's disease, 99–126,
211–222
lymphogranuloma venereum
(LGV), 26–40, 110–136
lysine decarboxylase test,
32–52
- MacConkey agar, 7–18, 30–46
macrolides. *See also specific
agents*
for *Bordetella pertussis*, 7–19
for *Campylobacter* species,
157–168
for CAP, 213–225
resistance to, 156–166
macrophages, 9–23
malaria, 36–59, 213–235
prophylaxis for, 218–233
Malassezia furfur, 34–56,
218–231
malathion, 68–72
malignancy
EBV association with, 97–124
HPV association with, 2–11
Streptococcus gallolyticus
association with, 33–54
mannitol salt agar, 30–46
maraviroc, 191–203
mastoiditis, 120–151
MCD (multicentric Castleman's
disease), 188–200
mcr-1 gene, 79–85
MDR (multidrug resistant)
tuberculosis, 82–90
measles, mumps and rubella
(MMR) vaccine, 180–184
measles virus, 97–123, 154–163
mefloquine, 218–233
melioidosis, 218–231
meningitis
cryptococcal, 103–129
Francisella tularensis, 212–223
Mycobacterium tuberculosis,
156–165
primary amoebic, 102–128
treatment for neonates,
158–170, 159–171,
159–171
meningococcal disease. *See
Neisseria meningitidis*
meropenem, 117–148,
160–174, 218–231
MERS (Middle East respiratory
syndrome), 220–235
metachromatic granules, 5–17
metal chelation, 162–178
metallo-beta-lactamases, 7–19
meticillin resistant
Staphylococcus aureus
(MRSA), 80–86
metronidazole, 80–88, 109–134
microcephaly
Toxoplasma gondii,
110–136
Zika virus, 212–223
microimmunofluorescence,
28–43
microscopy
electron, 1–9, 25–38
Enterobius vermicularis, 36–59
urine, 31–49
Microsporium species, 162–176
Middle East respiratory
syndrome (MERS),
220–235
Miles-Misra plates, 34–55
MLST (multilocus sequence
typing), 31–48
MMR (measles, mumps and
rubella) vaccine, 180–184
monitoring, drug, 156–176
Moraxella catarrhalis, 34–55
Morganella morganii, 5–15
moxifloxacin, 156–166
MRSA (meticillin resistant
Staphylococcus aureus),
80–86
multicentric Castleman's
disease (MCD), 188–200
multidrug resistant (MDR)
tuberculosis, 82–90
multilocus sequence typing
(MLST), 31–48
Mycobacterium kansasii, 28–42
Mycobacterium marinum,
112–138
Mycobacterium species
diagnostic tests for, 28–42
laboratory health and safety
for, 60–67
multidrug resistance in,
82–90
Mycobacterium tuberculosis.
See tuberculosis
myocarditis, *Corynebacterium
ulcerans*, 6–17
myositis, drug-induced, 160–174
NADPH oxidase, 8–22, 197–208
Naegleria fowleri, 102–128
naked DNA transformation, 6, 18
nalidixic acid, 29–43
necrotising fasciitis, 5–16
Neisseria gonorrhoea, 27–41,
118–149
Neisseria meningitidis, 8–21,
121–152
community contact
prophylaxis for, 69–75
healthcare worker
prophylaxis for, 69–74
laboratory worker infection
with, 61–64

- neomycin, 29–43
 neonates and infants
 bacterial infection in, 4–14
 Chlamydia trachomatis in,
 109–134
 CMV in, 98–132
 congenital rubella syndrome
 in, 26–40
 meningitis treatment for,
 158–171
 RSV in, 1–10
 sepsis in, 111–137
 syphilis in, 109–137
 nephropathy, HIV-associated,
 187–199
 nephrotoxicity,
 aminoglycoside, 160–173
 neuraminidase inhibitors,
 154–163. *See also specific
 agents*
 Nipah virus, 2–11
 nitrate test, 30–46
 nonnucleoside reverse
 transcriptase inhibitors
 (NNRTIs), 191–203
 norovirus, 69–76, 84–94
 nosocomial infection. *See*
 healthcare associated
 infection
 nucleic acid amplification tests.
 See polymerase chain
 reaction
 O antigens, 3–14
 obligate aerobes, 4–15
 obligate anaerobes, 4–15
Onchocerca volvulus, 219–233
 oseltamivir, 154–163
 otitis externa, 120–151
 ototoxicity, aminoglycoside,
 160–173
 ova, *Schistosoma haematobium*,
 31–49
Paecilomyces lilacinus, 194–206
 palivizumab, 1–10
 Panton-Valentine leukocidin
 (PVL), 5–16
 parainfluenza virus, 106–131
 Paramyxoviridae, 1–11
 parasites, 1, 110.30. *See also
 specific parasites*
 parvo virus B19, 2–11
 Parvoviridae, 1–11
 PAS (periodic acid-Schiff),
 35–57, 35, 35–57
Pasteurella multocida, 107–133
 PCR. *See* polymerase chain
 reaction
Pediculus humanus humanus,
 7–20
 penicillin, 109–137, 159–171
 penicilliosis, 190–201
 peptidoglycan (PGN), 4–15
 periodic acid-Schiff (PAS),
 35–57, 35, 35–57
 peri-operative antimicrobial
 prophylaxis, 112–139
 peripheral neuropathy,
 Corynebacterium ulcerans,
 6–17
 permethrin, 7–20, 68–72,
 108–134
 peroxymonosulphate, 66
 pertussis, 7–19, 68–72, 112–138
 PGN (peptidoglycan), 4–15
 phagocytes, 8–22, 197–208
 pharyngitis, *Streptococcus*
 species, 29–44, 100–126
 phase variation, bacterial, 6, 18
 photochromogens, 28–42
 pinworm, 36–59
 piperacillin-tazobactam,
 117–148
 PJP (*Pneumocystis jirovecii*
 pneumonia), 162–177,
 192–208
 plasmids, 3–13, 79–85
Plasmodium species. *See*
 malaria
 pneumococcal vaccine, 180–183
Pneumocystis jirovecii
 pneumonia (PJP, PCP),
 162–177, 192–208
 pneumonia
 Burkholderia pseudomallei,
 218–231
 Chlamydia psittaci, 28–43
 legionella, 113–140, 213–225
 Pneumocystis jirovecii,
 162–177, 162–177,
 192–204, 197–208
 RSV, 1–10
 Staphylococcus aureus,
 117–147, 117, 117–147
 in travelers, 213–225
 Pneumovirinae, 2–11
 polio virus, 2–11
 polymerase chain reaction (PCR)
 for *Chlamydia trachomatis*,
 26–43
 for herpesviridae, 25–39
 porous load autoclave, 83–91
 post-antibiotic effect, 155–164
 post-exposure prophylaxis
 for HIV, 191–204
 rabies, 24–37
 praziquantel, 214–234
 prednisolone, 180–183
 pregnancy
 antimicrobial safety
 categories for, 156–165
 antiretroviral therapy in,
 191–203
 asymptomatic bacteriuria in,
 115–143
 bacterial infection in, 4–14
 CMV infection in, 98–132
 HEV infection in, 106–131
 Listeria monocytogenes in,
 116–146
 malaria prophylaxis in,
 219–232
 syphilis in, 109–137
 Toxoplasma gondii in,
 110–136
 Ureaplasma urealyticum in,
 116–146
 vaccination during, 180–185
 Zika virus in, 212–223
 premature rupture of
 membranes, 116–146
 prevalence study, 82–89
 primaquine, 219–235
 primary amoebic
 meningoencephalitis,
 102–128
 probiotics, 162–178
 procaine penicillin, 109–135
 prosthetic joint infection,
 84–94, 113–139, 113–139
 prosthetic valve endocarditis
 (PVE), 103–129, 159–172
 proton pump inhibitors, 80–87,
 99–125
 prozone effect, 27–41, 217–230
 pruritis ani, 36–59
Pseudomonas aeruginosa, 4–17,
 29–44
 antibiotic resistance in,
 161, 161–175
 cystic fibrosis and,
 99–125
 genotyping of, 31–48
 in immunocompromised
 patients, 196, 198–209
 psittacosis, 28–43
 psychrophiles, 33–54

- public health, 68
 food-poisoning and diarrhoea outbreaks, 69–78
 haemolytic uraemic syndrome treatment, 71–77
 incubation periods, 70–76
 infections among abattoir workers, 69–73
 notification of officials, 70–75
 prophylaxis for community contacts, 69–75
 prophylaxis for healthcare workers, 69–74
 R_0 of diseases, 68–72
 reservoirs, 71–77
 risk of tuberculosis infection, 68–71
 scabies outbreaks, 68–72
 transmission routes, 71–78
 PVL (Panton-Valentine leukocidin), 5–16
 pyrazinamide, 156–166
 pyrimethamine, 188–200
- quick SOFA (qSOFA), 122–153
 quinine, 218–235
 quinupristin-dalfopristin, 7–18, 117–147
- R_0 , 68–72
 rabies virus, 24–37
 raltegravir, 191–204
 rash
Ancylostoma braziliense, 119–150
 dapson syndrome, 158–169
 epidemic typhus, 7–20
 Lyme's disease, 99–126, 211–222
Malassezia furfur, 34–56
 measles virus, 154–163
Onchocerca volvulus, 219–233
Sarcoptes scabiei, 68–72
 scabies, 108–134
 schistosomiasis, 8–20
 syphilis, 110–136, 217–230
 varicella zoster, 98–124
 reactive arthritis, 122–153
 rectal infection, *Chlamydia trachomatis*, 26–40
 Reiter's syndrome, 122–153
 relapsing fever, 5–17
 reservoirs, 71–77, 210–221
 respiratory failure
Bordetella pertussis, 112–138
 MERS, 220–235
Pseudomonas aeruginosa, 5–17, 99–125, 99–125
 respiratory isolation, 82–90, 213–225
 respiratory specimens, 35–58
 respiratory syncytial virus (RSV), 1–10
 rhinocerebral zygomycosis, 35–57
 ribavirin, 155–163
Rickettsia prowazekii, 7–20
 rifampicin, 70–75, 156–175
 rimantidine, 154–163
 rituximab, 188–200
 RNA polymerase inhibitors, 157–167
 RNA viruses, 1–10
 roseola infantum, 193–205
 rotavirus, 69–76
 RSV (respiratory syncytial virus), 1–10
 rubella virus, 2–11, 26–40
 Runyon classification, 28–42
- safety cabinets, 60–62
 safranin, 3–12
Salmonella Arizonae, 31–49, 116–144
Salmonella Paratyphi, 32–52, 215–229
Salmonella species, 29–44
 diagnostic tests for, 31–54
 diarrhoea, 3–14, 34–54, 116–144
 in immunocompromised patients, 197–208
 incubation period of, 70–76
 spread of, 68–72
Salmonella Typhi, 32–50, 69–77, 83–92, 215–230
Salmonella Typhimurium, 83–92
 sanitisation, 81–88
Sarcoptes scabiei, 68–72, 108–134
Schistosoma haematobium, 8–20, 31–49, 31–49, 214, 219–234, 214–226
 SCID (severe combined immunodeficiency), 8–21
 scotochromogens, 28–42
 seafood, 33–52, 107–132, 197–208, 214–228
 seizure, drug-induced, 160–174
 selective media, 29–54
 sepsis, 122–153
Capnocytophaga canimorsus, 107–133
Escherichia coli, 117–148
 neonate with, 111–137
Vibrio vulnificus, 107–144
 septic shock, 4–16
Klebsiella pneumoniae, 122–152
 septicæmia, diphtheria, 118–148
 Sequential Organ Failure Assessment (SOFA), 122–153
 seroconversion illness, 187–198
 serology, *Salmonella* species, 32–50
 settle plates, 84–95
 severe combined immunodeficiency (SCID), 8–21
 shell fish, 115–144, 197–208
Shigella species, 29–44
 diagnostic tests for, 33–54
 diarrhoea, 34–54, 70–75, 116–145
 incubation period of, 70–76
 public health notification of, 70–75
 transmission of, 71–78
 sickle cell anaemia, 2–11
 single stranded DNA viruses, 1–10
 single stranded RNA viruses, 1–9, 10, 1–10
 slaughterhouse workers, 69–73
 snail-borne disease, 8–20
 SOFA (Sequential Organ Failure Assessment), 122–153
 spastic paraparesis, 97–123
 specimens
 blood, 61–66
 faecal (*See* faecal specimens)
 respiratory, 35–58
 safe transport of, 61–65
 urine, 30–49, 115–143
 vomit, 32–51
 spermicidal gel, 114–141
 spiramycin, 110–136
 sputum, safe handling of, 60–62, 60–62
 SSPE (subacute sclerosing panencephalitis), 97–123
 staining
 Albert's, 5–17
 Field's and Giemsa, 36–59
 fungi, 35–58
 Gram (*See* Gram stain)
 India Ink, 103–129

- Staphylococcus aureus*, 29–44
 antibiotic resistance of, 155–164
 bacteraemia, 114–141, 159–172
 diagnostic tests for, 34–55
 food poisoning, 69–73
 genotyping of, 31–48
 meticillin resistant, 80–86
 necrotising fasciitis caused by, 5–16
 pneumonia, 117–147
 treatment of, 159–172
 UTI, 114–141
- Staphylococcus epidermidis*, 113–139
- Staphylococcus haemolyticus*, 29–45
- Staphylococcus saprophyticus*, 115–143
- stem cell transplant, 161–177, 195–207
- Stenotrophomonas maltophilia*, 118–148
- sterile pyuria, 115–143
- sterilization, 81–91
- steroids, 180–183
- stool electron microscopy, 25–38
- stool samples
 cholera, 215–229
 culture of, 31–51, 214–228
 transport media for, 32–51
- Streptococcus dysgalactiae*, 29–44
- Streptococcus gallolyticus*, 33–54
- Streptococcus pneumoniae*, 6, 18, 34–55, 213–225
- Streptococcus pyogenes*, 29–44, 100–126
- Streptococcus* species
 group A, 29–44, 100–126
 group B, 4–14, 159–171
 group C, 29–44
- streptomycin, 117–147, 156–165, 212–223
- strongyloidiasis, 214–235
- subunit vaccines, 179–182
- sulphadiazine, 188–200
- swimmers ear, 120–151
- syphilis, 27–41, 109–149, 217–230
- tacrolimus, 193–207
- target alteration, 156–166
- TCBS (Thiosulfate-Citrate-Bile-Sucrose) agar, 33–52
- teichoic acid, 4–15
- teicoplanin, 29–45
- terminal void urine, 31–49
- tetanus, 24–37
- Th1 response, 9–23
- Th2 response, 9–23
- therapeutic drug monitoring.
See drug monitoring
- thermophiles, 33–54
- thiabendazole, 119–150, 220–235
- Thiosulfate-Citrate-Bile-Sucrose (TCBS) agar, 33–52
- tick-borne diseases, 99–126, 211–223
- tigecycline, 122–152
- tinea capitis, 162–176, 218–231
- tinea versicolor, 34–56
- toll-like receptors (TLRs), 9–22
- tonsillitis, 120–151
- topoisomerase IV, 157–166
- toxic shock syndrome toxin-1 (TSST-1), 5–16
- toxins, bacterial, 4–22, 32–51, 105–130
- toxoid vaccines, 179–182
- Toxoplasma gondii*, 110–136, 188–200
- transduction, 3–13
- transformation, 3–13, 18
- transmission routes, 71–78
- transport, specimen, 61–65
- transport media, 32–51
- travel, 210
 asymptomatic health screen after, 220–235
 malaria prophylaxis for, 218–233
 pneumonia and, 213–225
 vaccination for, 180–186
 travellers' diarrhoea, 116–145, 214–227
- trench mouth, 26–40
- Treponema pallidum*, 27–41, 109–149, 217–230
- Trichomonas vaginalis*, 109–134
- truvada, 191–204
- TSST-1 (toxic shock syndrome toxin-1), 5–16
- tuberculosis
 contact tracing for, 83–91
 increased risk for, 68–71
- laboratory health and safety for, 60–67
- laboratory worker infection with, 61–64
- meningitis, 156–165
- prevention and control of, 82–91
- treatment of, 156–172
- tularaemia, 212–223
- tumbling motility, 4–14
- turtles, 116–144
- typhoid fever. *See* enteric fever
- typhus, 7–20
- ultra clean ventilated (UCV) theatres, 84–94
- UN3373, 61–65
- Ureaplasma urealyticum*, 116–146
- urease, bacteria producing, 5–15
- urethral catheterization, 114–142, 115–142
- urethral stricture, 118–149
- urethritis, 118–149
- urinary tract infection (UTI)
 catheter-associated, 114–142
 cognitive decline and, 115–143
 diagnostic tests for, 30–47, 115–143
Escherichia coli, 5–15, 114–140
 frequency of, 114–141
Staphylococcus aureus, 114–141
 sterile pyuria, 115–143
 in women compared with men, 114–141
- urine specimens, 30–49, 115–143
- urosepsis
 bacterial toxins in, 5–22
Klebsiella pneumoniae, 7–19
- vaccination, 179
Bordetella pertussis, 7–19
 HBV, 179–181
 in immunocompromised patients, 179–183
 influenza virus, 179–182
 MMR, 180–184
 pneumococcal, 180–183
 rabies, 24–37
 schedules for, 180–184
 types of, 179–181
 varicella zoster, 180–183

- Vibrio cholerae*, 180–184
yellow fever, 180–186
vaginal discharge, *Trichomonas vaginalis*, 109–134
valaciclovir, 110–135
valganciclovir, 98–125
valproate, 160–174
vancomycin, 29–43, 81–88, 117–147
varicella zoster, 98–124, 180–183
VDRL (venereal disease reference laboratory) test, 112–149, 217–230
vectors, 7–20
venlafaxine, 158–170
VHF (viral haemorrhagic fever), 213–224
Vi antigen, 3–14
Vibrio cholerae, 33–52, 180–184, 214–229
Vibrio parahaemolyticus, 197–208, 214–228, 214–228
Vibrio vulnificus, 107–144, 214–228
- Vincent's angina, 26–40
viral haemorrhagic fever (VHF), 213–224
virulence factors, bacteria, 5–16, 6, 5–16, 18
viruses, 1. *See also specific viruses*
classification of, 1–11, 79–85
DNA, 1–10
envelope of, 1–9, 79–85
immunoglobulins in
diagnosis of, 8–21
natural histories of, 2–12
RNA, 1–10
structure of, 1–9
vitamin B₁₂ deficiency, 210–221
volutin granules, 5–17
vomiting
anisakiasis, 214–227
diagnostic tests for, 25–51
Escherichia coli, 214–227
outbreaks of, 69–73, 82–94
Vibrio species, 107–132, 215–229
voriconazole, 161–177, 196–207
- ward closure, 82–93
warfarin, 159–172, 219–233
watery diarrhoea
Cryptosporidium parvum, 215–228
cyclosporiasis, 32–50
rotavirus, 70–75
Vibrio cholerae, 215–229
whole genome sequencing, 31–48
whooping cough. *See* pertussis
work, return to, 83–92
workplace-associated infection, among laboratory workers, 61–64
xylose lysine desoxycholate (XLD) agar, 30–54
yellow fever vaccination, 180–185, 181–186
Yersinia enterocolitica, 116–145
Zika virus (ZIKV), 212–223
zoster, 98–124